Literature DB >> 24551022

"Pulmonary hypertension in Saudi Arabia: A single center experience," which was published in the previous issue of Annals of Thoracic Medicine.

Majdy Idrees1.   

Abstract

Entities:  

Year:  2014        PMID: 24551022      PMCID: PMC3912691          DOI: 10.4103/1817-1737.124447

Source DB:  PubMed          Journal:  Ann Thorac Med        ISSN: 1998-3557            Impact factor:   2.219


× No keyword cloud information.
Sir, We read with great interest the article by Alhamad et al.,[1] entitled “Pulmonary hypertension in Saudi Arabia: A single center experience,” which was published in the previous issue of Annals of Thoracic Medicine. The authors are to be congratulated for publishing the first comprehensive data about pulmonary hypertension (PH) in Saudi Arabia. However, two points are worth commenting upon. First, the authors had submitted 264 patients with suspected PH to invasive right heart catheterization. Out of those, only 152 studies were diagnostic (57.6%). The screening method used by the authors has depended upon suspicion of PH on clinical examination, when a marked reduction in the predicted DLCO <40% was noted, when oxygen desaturation <88% was evident during the 6-min walk test, or when indicated by the results of chest radiography, computed tomography, and/or echocardiography. Being that significant number of enrolled patients (49.3%) had belonged to World Health Organization group III disease (mostly interstitial lung disease in this study), such screening criteria were proved to be very insensitive and lead to over studying these patients invasively. Second, the authors have shown their practice in treating all PH groups (except group II) by pulmonary arterial hypertension (PAH) specific therapy. Many of studies have shown conflicting results regarding the efficacy and safety of using PAH drugs in non-PAH patients[2345] and all clinical guidelines and drug regularity authorities have asked for enrolling patients in clinical trials before subjecting those patients to this class of therapy. Until date, such therapy has not been approved for the treatment of non-PAH groups, including PH groups III and V. Hence, we wonder whether the patients studied by the authors in this particular study were actually enrolled in controlled trials or this indeed reflected the authors’ practice. In conclusion, the study by Alhamad et al., was very interesting, and to be considered as a great initiative effort in describing PH management in Saudi Arabia; however, we believe that treating this very complex disease need to be comprehensive and should be always obligated to the international guidelines recommendations.[6]
  5 in total

1.  Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon.

Authors:  Stephan Rosenkranz; Frank Diet; Thomas Karasch; Julia Weihrauch; Klaus Wassermann; Erland Erdmann
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

2.  [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].

Authors:  H Olschewski; H A Ghofrani; D Walmrath; R Schermuly; B Temmesfeld-Wollbrück; F Grimminger; W Seeger
Journal:  Pneumologie       Date:  2000-03

3.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

4.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Authors:  Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Ralph T Schermuly; Horst Olschewski; Norbert Weissmann; Andreas Gunther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

5.  Pulmonary hypertension in Saudi Arabia: A single center experience.

Authors:  Esam H Alhamad; Joseph G Cal; Hussam F Alfaleh; Mostafa Q Alshamiri; Ahmad A Alboukai; Suliman A Alhomida
Journal:  Ann Thorac Med       Date:  2013-04       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.